Stocks
Alder Biopharmaceuticals IncALDR
HealthcareBiotechnology
A clinical-stage biopharmaceutical company developing monoclonal antibodies for migraine and other pain-related conditions. Its lead product, an anti-CGRP antibody, was acquired by Lundbeck in 2019, and the company ceased operations shortly after. Investors tracked ALDR for its potential in the competitive migraine treatment market.
Congressional Interest in Alder Biopharmaceuticals Inc (ALDR)
1 member of Congress has disclosed 1 trade in Alder Biopharmaceuticals Inc (ALDR), a Healthcare company. The buy/sell breakdown shows 0 purchases versus 1 sale, indicating net selling pressure from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
1
Unique Politicians
1
Buys
0
Sells
1
Who in Congress Is Trading ALDR?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2020-10-01 | MICHAEL T. MCCAUL | sell | $50K-$100K |